HC Wainwright Has Negative View of AngioDynamics Q1 Earnings

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 EPS estimates for AngioDynamics in a research report issued on Wednesday, July 16th. HC Wainwright analyst Y. Chen now forecasts that the medical instruments supplier will post earnings per share of ($0.14) for the quarter, down from their prior forecast of ($0.12). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics' Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.30) EPS.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group set a $17.00 price objective on AngioDynamics and gave the company a "buy" rating in a research report on Wednesday. Lake Street Capital assumed coverage on AngioDynamics in a research report on Wednesday. They issued a "buy" rating and a $24.00 price objective for the company.

AngioDynamics Stock Down 0.6%

AngioDynamics stock traded down $0.05 during midday trading on Friday, reaching $8.69. The stock had a trading volume of 719,749 shares, compared to its average volume of 589,653. AngioDynamics has a 12 month low of $5.83 and a 12 month high of $13.50. The firm's 50-day moving average price is $9.86 and its 200 day moving average price is $10.06. The firm has a market capitalization of $352.90 million, a PE ratio of -10.47 and a beta of 0.60.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. The business had revenue of $80.16 million during the quarter, compared to the consensus estimate of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.06) EPS.

Institutional Trading of AngioDynamics

Large investors have recently added to or reduced their stakes in the company. Quinn Opportunity Partners LLC purchased a new stake in AngioDynamics in the fourth quarter valued at about $92,000. ProShare Advisors LLC purchased a new stake in AngioDynamics in the fourth quarter valued at about $100,000. Graham Capital Management L.P. purchased a new position in shares of AngioDynamics in the fourth quarter worth about $106,000. OneDigital Investment Advisors LLC raised its stake in shares of AngioDynamics by 14.0% in the fourth quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock worth $111,000 after purchasing an additional 1,490 shares during the last quarter. Finally, Cerity Partners LLC raised its stake in shares of AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock worth $121,000 after purchasing an additional 2,333 shares during the last quarter. Institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.